Insight Molecular Diagnostics Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Insight Molecular Diagnostics Inc. (IMDX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $15.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-26
- Insight Molecular Diagnostics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $15.20M.
- Insight Molecular Diagnostics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$2.90M.
- Insight Molecular Diagnostics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2017 was $1.10M, a 78.43% decline from fiscal 2016.
- Insight Molecular Diagnostics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $5.10M, a 30.77% increase from fiscal 2015.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $15.20M 10-K · filed 2026-03-26 |
| 2024-12-31 | -$2.90M 10-K · filed 2026-03-26 |
| 2017-12-31 | $1.10M 10-K · filed 2018-04-02 |
| 2016-12-31 | $5.10M 10-K · filed 2018-04-02 |
| 2015-12-31 | $3.90M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |